Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy

NCT04566432 is registered in ClinicalTrials.gov with Geneplus-Beijing Co. Ltd. as lead sponsor.

NCT NCT04566432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04566432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy
Lead sponsor
Geneplus-Beijing Co. Ltd.
Phase
Observational
Overall status
Completed
Start date
July 1, 2020
Completion date
December 31, 2025
Enrollment
252 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, lung cancer, nonsmall cell, lung neoplasms, squamous cell lung cancer